摘要 |
<p>Compounds represented by general formula (I) (wherein A represents a C<sub>3-12</sub> cycloalkyl group optionally substituted by 1-3 substituents selected from among fluoro groups, hydroxide groups and/or a C<sub>1-6</sub> alkyl groups; R1, R2 and R3 each individually represents a hydrogen atom, a fluoro group or a C<sub>1-6</sub> alkyl group; R4 represents a hydrogen atom or a prodrug group;and Y represents -CH<sub>2</sub>-CHR5-CH<sub>2</sub>-NHR6, in which R5 represents a hydrogen atom, a C<sub>1-6</sub> alkyl group or a C<sub>1-6</sub> alkoxy group and R6 represents a hydrogen atom or a prodrug group) and pharmacologically-acceptable salts thereof exhibit a TAFIa-inhibiting activity, and thus are useful as therapeutic drugs for myocardial infarction, angina, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, etc.</p> |
申请人 |
DAIICHI SANKYO COMPANY, LIMITED |
发明人 |
NAGATA, TSUTOMU;ONO, MAKOTO;INOUE, MASAHIRO;ASHIDA, YUKA;NOGUCHI, KENGO |